Incidence and risk factor analysis for sarcopenia in patients with cancer

  • Authors:
    • Guoxing Zhang
    • Xiujiang Li
    • Changping Sui
    • Hui Zhao
    • Jihong Zhao
    • Yue Hou
    • Yujun Du
  • View Affiliations

  • Published online on: December 9, 2015     https://doi.org/10.3892/ol.2015.4019
  • Pages: 1230-1234
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The objective of the present study was to investigate the incidence of and possible risk factors associated with sarcopenia among cancer patients. Patients with cancer were examined through the use of lumbar magnetic resonance imaging, and clinical data was collected between September and December, 2012, at Jilin Province Tumor Hospital (Changchun, China). The data was subsequently compared between patients with and without sarcopenia. Of the 113 treated cancer patients, 96 patients [39 males (L3 index, <52.4 cm2/m2) and 57 females (L3 index, <38.5 cm2/m2)] suffered from sarcopenia. Overall, the development of sarcopenia was not significantly associated with patient age or treatment, including surgery, chemotherapy or radiotherapy (P>0.05). The frequency of treatment‑associated complications did not differ significantly between patients with or without sarcopenia. However, males were more inclined to develop sarcopenia than females (P=0.02). Patients with sarcopenia had significantly less lymphocytes than patients without sarcopenia (P=0.03). This was confirmed through multiple logistic regression analyses (P=0.046), which also identified that patients with cancer with an Eastern Cooperative Oncology Group score >2 had a significantly increased risk of developing sarcopenia. Finally, the serum albumin level in sarcopenia patients was 36.18±4.65 g/l, which was not significantly less than that of patients without sarcopenia (39.67±3.69 g/l; P=0.11). The incidence of sarcopenia among patients with cancer is high, particularly for males. Further research with larger sample sizes would be beneficial, with the aim of verifying the results obtained in the present study. During the treatment of patients with sarcopenia, precaution should continue to be taken to prevent associated complications, including infection, diarrhea and myelosuppression.
View Figures
View References

Related Articles

Journal Cover

February-2016
Volume 11 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang G, Li X, Sui C, Zhao H, Zhao J, Hou Y and Du Y: Incidence and risk factor analysis for sarcopenia in patients with cancer. Oncol Lett 11: 1230-1234, 2016
APA
Zhang, G., Li, X., Sui, C., Zhao, H., Zhao, J., Hou, Y., & Du, Y. (2016). Incidence and risk factor analysis for sarcopenia in patients with cancer. Oncology Letters, 11, 1230-1234. https://doi.org/10.3892/ol.2015.4019
MLA
Zhang, G., Li, X., Sui, C., Zhao, H., Zhao, J., Hou, Y., Du, Y."Incidence and risk factor analysis for sarcopenia in patients with cancer". Oncology Letters 11.2 (2016): 1230-1234.
Chicago
Zhang, G., Li, X., Sui, C., Zhao, H., Zhao, J., Hou, Y., Du, Y."Incidence and risk factor analysis for sarcopenia in patients with cancer". Oncology Letters 11, no. 2 (2016): 1230-1234. https://doi.org/10.3892/ol.2015.4019